StreetInsider.com News Articles

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 22 Jun 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260622/26674238.html

Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 22 Jun 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20260622/26674238.html

Form S-8 RELMADA THERAPEUTICS,

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665961.html

Form S-8 RELMADA THERAPEUTICS,

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665961.html

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.

The analyst comments "What’s new? We are initiating coverage of Relmada Therapeutics with a Buy rating and $12 price target, with our thesis centered on NDV-01 as a differentiated sustained-release intravesical formulation of gemcitabine/docetaxel, or Gem/Doce, for non-muscle invasive bladder cancer. In our view, NDV-01 is best understood as a next-generation delivery platform for a familiar and increasingly validated intravesical chemotherapy backbone rather than a wholly novel therapeutic modality. This distinction matters because Gem/Doce has already gained meaningful

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.

H.C. Wainwright Starts Relmada Therapeutics Inc (RLMD) at Buy, PT $12

Thu, 18 Jun 2026 05:59:53 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Relmada Therapeutics Inc (NASDAQ: RLMD) with a Buy rating and a price target of $12.00.

Relmada appoints Michael Quirk as senior advisor for sepranolone program

Thu, 11 Jun 2026 07:02:13 -0400

Relmada Therapeutics Inc. (NASDAQ: RLMD) appointed Michael Quirk as Senior Advisor for its sepranolone program. Quirk brings over 20 years of neuroscience drug discovery and development experience, including his previous role as Chief Scientific Officer at Sage Therapeutics.

Sepranolone is a GABAA receptor modulator being developed to treat Prader-Willi Syndrome and other central nervous system disorders. The drug selectively antagonizes allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling.

"His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology," said

Relmada appoints Michael Quirk as senior advisor for sepranolone program

Thu, 11 Jun 2026 07:02:13 -0400

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program